Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2026 19:24 ET | Source: AgomAb Therapeutics N.V.

Agomab Announces Pricing of Initial Public Offering

Agomab today announced the pricing of its initial public offering of 12,500,000 ADSs representing 12,500,000 of its common shares.
February 02, 2026 07:00 ET | Source: AgomAb Therapeutics N.V.

Agomab Announces Launch of Initial Public Offering

Agomab today announced the launch of its initial public offering of 12,500,000 ADSs pursuant to a registration statement filed with the SEC.
January 08, 2026 05:00 ET | Source: AgomAb Therapeutics N.V.

Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

Agomab today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants.
November 17, 2025 01:00 ET | Source: AgomAb Therapeutics N.V.

Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease

Agomab announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA1 Phase 2a clinical trial for ontunisertib (AGMB-129)
May 06, 2025 15:00 ET | Source: AgomAb Therapeutics N.V.

Late-Breaking Interim STENOVA Data Presented at Digestive Disease Week® 2025 Demonstrate Potential of AGMB-129 in Fibrostenosing Crohn’s Disease

Antwerp, Belgium, May 6, 2025 – Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal...